ALC vs SYK vs BSX Stock Comparison

Alcon, Stryker and Boston Scientific Prices as of Nov 13, 2026 Peers: Industry group
ALC Alcon Inc
$74.13 +16.0% 1M -5.7% 1Y
Market cap
$36.45B
P/E
54.7x
Revenue (TTM)
$10.93B
Div. yield
–
Medical Devices Healthcare
2 wins
SYK Stryker Corp
$309.54 +9.9% 1M -17.1% 1Y
Market cap
$118.80B
P/E
32.8x
Revenue (TTM)
$26.30B
Div. yield
–
Medical Devices Healthcare
3 wins
BSX Boston Scientific Corp
$44.34 +3.1% 1M -57.8% 1Y
Market cap
$63.53B
P/E
18.1x
Revenue (TTM)
$21.07B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

11 decided of 12

Boston Scientific leads on 6 of the 12 questions below (Boston Scientific 6, Stryker 3, Alcon 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALCSYKBSXLeader
Larger companyMarket capitalisation $36.45B $118.80B $63.53B SYK
Cheaper on earningsLower P/E, profitable companies only 54.7x 32.8x 18.1x BSX
Cheaper on forward earningsLower price / next fiscal year consensus EPS 23.0x 19.6x 14.5x BSX
Faster revenue growthRevenue growth, trailing twelve months +8.0% +7.9% +8.9% BSX
More profitableNet margin, trailing twelve months 6.1% 13.8% 16.6% BSX
Better return on capitalReturn on invested capital 3.8% 10.0% 9.9% SYK
Less leveragedLower net debt / EBITDA — 3.5x 2.1x BSX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -5.7% -17.1% -57.8% ALC
Better 5-year returnAnnualised price return, 5 years -1.8%/yr +3.2%/yr +1.1%/yr SYK
Less volatileAnnualised volatility, 1 year 29.5% 32.9% 41.5% ALC
Higher overall scoreMean of the five percentile scores vs peers 67/100 67/100 68/100 BSX

Percentile Scorecard

ALCSYKBSX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALCSYKBSX
Valuation 77 #57 of 243 66 #84 of 243 87 #33 of 243
Growth 45 #126 of 228 63 #85 of 228 68 #73 of 228
Profitability 78 #49 of 222 88 #28 of 222 91 #20 of 222
Financial Health 64 #89 of 248 42 #144 of 248 43 #142 of 248
Shareholder Returns 71 #46 of 158 78 #35 of 158 48 #82 of 158
Overall 67 67 68
  • ALC ranked among 252 companies in Medical Devices and Diagnostics
  • SYK ranked among 252 companies in Medical Devices and Diagnostics
  • BSX ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALCSYKBSXSPY
1 month +16.0%+9.9%+3.1% -2.0%
3 months -0.2%-8.6%-14.5% -2.8%
6 months +16.5%+0.9%-15.8% +2.0%
Year to date -5.9%-11.9%-53.5% +10.6%
1 year -5.7%-17.1%-57.8% +12.2%
3 years -1.1%+9.4%-17.9% +68.1%
3 years, per year -0.4%+3.0%-6.4% +18.9%
5 years -8.7%+17.1%+5.4% +61.4%
5 years, per year -1.8%+3.2%+1.1% +10.1%
10 years —+180.5%+106.2% +248.5%
10 years, per year —+10.9%+7.5% +13.3%

Risk

MeasureALCSYKBSXSPY
Volatility, 1Y 29.5%32.9%41.5% 13.6%
Downside volatility, 1Y 29.2%32.8%47.7% 13.9%
Beta vs S&P 500, 1Y 0.370.280.26 1.00
Return / volatility, 1Y -0.19-0.52-1.39 0.90
Max drawdown, 5Y -38.4%-33.1%-61.6% -25.4%
From 52-week high -15.0%-20.1%-57.8% -3.2%
52-week high $87.18$387.46$104.98 $779.14
52-week low $62.02$269.88$41.57 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALCSYKBSX
P/E now vs peer median 54.9xmedian 26.5x 32.7xmedian 26.5x 18.3xmedian 26.5x
P/S now vs peer median 3.3xmedian 2.7x 4.5xmedian 2.7x 3.1xmedian 2.7x
EV/EBITDA now vs peer median —median 18.4x 38.6xmedian 18.4x 14.1xmedian 18.4x
P/FCF now vs peer median 20.4xmedian 25.4x 25.8xmedian 25.4x 19.3xmedian 25.4x
P/B now vs peer median 1.7xmedian 2.5x 5.0xmedian 2.5x 2.5xmedian 2.5x
PEG now vs peer median 3.97median 0.98 2.76median 0.98 0.42median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALCSYKBSX
Revenue $10.93B $26.30B $21.07B
Gross profit $6.34B $17.18B $14.57B
Operating income $997.00M $5.43B $3.93B
Net income $666.00M $3.62B $3.49B
Free cash flow $1.77B $4.57B $3.33B
R&D $1.44B $1.68B $2.16B
EPS (diluted) $1.34 $9.42 $2.41
Cash & equivalents $1.71B $3.27B $609.00M
Total debt $4.69B $14.93B $11.95B
Shares (diluted) 496.20M 384.70M 1.45B
Enterprise value $27.16B $104.99B $58.97B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALCSYKBSX
P/E 54.9x 32.7x 18.3x
P/FCF 20.4x 25.8x 19.3x
P/Operating cash flow 15.4x 21.6x 15.2x
P/S 3.3x 4.5x 3.1x
P/B 1.7x 5.0x 2.5x
P/Tangible book 2.7x 6.6x 3.4x
EV/EBITDA – 38.6x 14.1x
EV/EBIT 38.4x 23.8x 19.2x
EV/Revenue 3.5x 4.9x 3.6x
EV/FCF 21.6x 28.3x 22.7x
EV/Operating cash flow 16.3x 23.8x 17.9x
PEG (3Y EPS CAGR) 3.97 2.76 0.42

Growth

14 metrics
MetricALCSYKBSX
Revenue growth (1Y) 8.0% 7.9% 8.9%
Revenue CAGR (3Y) 5.6% 9.8% 15.3%
Gross profit growth (1Y) 12.9% 10.1% 9.8%
Gross profit CAGR (3Y) 7.3% 10.9% 15.1%
Operating income growth (1Y) -30.9% 48.2% 13.5%
Operating income CAGR (3Y) 5.4% 16.4% 22.1%
Net income growth (1Y) -36.4% 23.1% 25.5%
Net income CAGR (3Y) 14.0% 11.9% 41.7%
EPS growth (1Y) -37.1% 23.7% 29.2%
EPS CAGR (3Y) 13.8% 11.8% 44.0%
Operating cash flow growth (1Y) 13.3% 12.7% -8.5%
Operating cash flow CAGR (3Y) 22.3% 19.6% 21.6%
Free cash flow growth (1Y) 7.5% 12.3% -12.9%
Free cash flow CAGR (3Y) 44.0% 21.2% 25.2%

Profitability

14 metrics
MetricALCSYKBSX
Gross margin 58.0% 65.3% 69.1%
EBITDA margin – 12.8% 25.5%
Operating margin 9.1% 20.7% 18.7%
Pretax margin 7.2% 19.5% 17.3%
Net margin 6.1% 13.8% 16.6%
FCF margin 16.2% 17.4% 15.8%
Operating cash flow margin 21.5% 20.7% 20.1%
Return on equity 3.1% -4.0% 13.7%
Return on assets 2.1% -2.0% 7.7%
Return on invested capital 3.8% 10.0% 9.9%
Return on capital employed 3.5% 13.2% 10.0%
Asset turnover 0.3x 0.6x 0.5x
Cash conversion (OCF / net income) 3.5x 1.5x 1.2x
Stock comp / revenue 1.5% 1.0% 1.5%

Financial Health

11 metrics
MetricALCSYKBSX
Debt / assets 14.9% 31.6% 26.3%
Debt / equity 0.2x 0.6x 0.5x
Net debt / EBITDA – 3.5x 2.1x
Debt / FCF 2.6x 3.3x 3.6x
Liabilities / assets 30.7% 50.4% 43.1%
Equity / assets 69.3% 49.6% 56.9%
Interest coverage 9.6x 9.3x 10.5x
Current ratio 2.5x 2.2x 1.4x
Quick ratio 1.6x 1.1x 0.6x
Cash ratio 0.9x 0.5x 0.1x
Altman Z-score – 4.73 3.03

Shareholder Returns

7 metrics
MetricALCSYKBSX
Dividend yield 0.4% 1.1% –
Net buyback yield 1.3% – -0.3%
Shareholder yield 1.7% 1.1% -0.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALCSYKBSX
Forward P/E 23.0xFY2026 19.6xFY2026 14.5xFY2026
EPS, next fiscal year $3.22FY2026 $15.79FY2026 $3.06FY2026
EPS growth, next FY +7.7%FY2026 +15.8%FY2026 0.0%FY2026
EPS growth, the year after +14.0% +0.9% +8.2%
Revenue, next fiscal year $10.48BFY2026 $25.79BFY2026 $20.48BFY2026
Revenue growth, next FY +4.1%FY2026 +2.7%FY2026 +2.1%FY2026
Revenue growth, the year after +7.9% +16.5% -4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALCSYKBSX
Held by institutions 48.8% 80.3% 90.5%
Institutions holding 631 2,267 1,484
Change in shares held, QoQ +5.3% +3.1% -0.7%
Institutions buying 226 1,105 738
Institutions selling 274 852 612
Buyers to sellers 0.82 1.30 1.21

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALCSYKBSX
ALC 1.00 0.52 0.31
SYK 0.52 1.00 0.44
BSX 0.31 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALC, SYK and BSX?

Stryker (SYK) is the largest by market capitalisation: Alcon (ALC) $36.45B, Stryker (SYK) $118.80B, Boston Scientific (BSX) $63.53B.

Which stock is cheaper, ALC, SYK and BSX?

Boston Scientific (BSX) trades on the lowest price-to-earnings ratio (Alcon (ALC) 54.7x, Stryker (SYK) 32.8x, Boston Scientific (BSX) 18.1x). On next year's consensus earnings, Boston Scientific (BSX) is cheapest (Alcon (ALC) 23.0x, Stryker (SYK) 19.6x, Boston Scientific (BSX) 14.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Boston Scientific (BSX) grew revenue fastest over the trailing twelve months: Alcon (ALC) +8.0%, Stryker (SYK) +7.9%, Boston Scientific (BSX) +8.9%.

Which company is more profitable?

Boston Scientific (BSX) has the highest net margin (Alcon (ALC) 6.1%, Stryker (SYK) 13.8%, Boston Scientific (BSX) 16.6%). On return on invested capital, Stryker (SYK) leads (Alcon (ALC) 3.8%, Stryker (SYK) 10.0%, Boston Scientific (BSX) 9.9%).

Which stock has performed better?

Over the past year Alcon (ALC) returned the most: Alcon (ALC) -5.7%, Stryker (SYK) -17.1%, Boston Scientific (BSX) -57.8%. Over five years, Stryker (SYK) compounded fastest (Alcon (ALC) -1.8%/yr, Stryker (SYK) +3.2%/yr, Boston Scientific (BSX) +1.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Alcon (ALC) has been the steadiest (Alcon (ALC) 29.5%, Stryker (SYK) 32.9%, Boston Scientific (BSX) 41.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALC, SYK and BSX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Boston Scientific (BSX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.